Overview

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single or multiple oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single or multiple oral dose.
Phase:
Phase 1
Details
Lead Sponsor:
KT&G Life Sciences Corp
Yungjin Pharm. Co., Ltd.
Collaborator:
KT&G Corporation
Treatments:
Beta-lapachone